ArticleJournal of Cancer2019
The Identification of Potential Biomarkers and Biological Pathways in Prostate Cancer.
Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Unravelling TPX2-centered co-expression networks as key drivers of aggressive prostate cancer.Scientific reports · 2025Article
- DiCE: differential centrality-ensemble analysis based on gene expression profiles and protein-protein interaction network.Nucleic acids research · 2025Article
- RNA-Seq Uncovers Association of Endocrine-Disrupting Chemicals with Hub Genes and Transcription Factors in Aggressive Prostate Cancer.International journal of molecular sciences · 2025Article
- In Vitro and In Silico Evaluation of the Potential Anti-Prostate Cancer Activity ofInternational journal of molecular sciences · 2025Article
- Transcriptomic signatures of prostate cancer progression: a comprehensive RNA-seq study.3 Biotech · 2025Article
- DiCE: differential centrality-ensemble analysis based on gene expression profiles and protein-protein interaction network.bioRxiv : the preprint server for biology · 2025Article
- Cabozantinib and IL-27 combinatorial therapy for bone-metastatic prostate cancer.Frontiers in molecular biosciences · 2023Article
- Identification of UAP1L1 as a critical factor for prostate cancer and underlying molecular mechanism in tumorigenicity.Journal of translational medicine · 2022Article
- Suppression of CDCA3 inhibits prostate cancer progression via NF‑κB/cyclin D1 signaling inactivation and p21 accumulation.Oncology reports · 2022Article
- Overexpression of CDCA8 Predicts Poor Prognosis and Promotes Tumor Cell Growth in Prostate Cancer.Frontiers in oncology · 2022Article
- Identification and Validation of Three Hub Genes Involved in Cell Proliferation and Prognosis of Castration-Resistant Prostate Cancer.Oxidative medicine and cellular longevity · 2022Article
- Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis.Bioengineered · 2021Article
- Article
- Limitations of Explainability for Established Prognostic Biomarkers of Prostate Cancer.Frontiers in genetics · 2021Article
- Identification of UBE2C as hub gene in driving prostate cancer by integrated bioinformatics analysis.PloS one · 2021Article
- Article
- Molecular MR Imaging of Prostate Cancer.Biomedicines · 2020Review
- Article
- FOXM1 modulates docetaxel resistance in prostate cancer by regulating KIF20A.Cancer cell international · 2020Article
- Comprehensive analysis of biomarkers for prostate cancer based on weighted gene co-expression network analysis.Medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.